230 related articles for article (PubMed ID: 37047621)
1. STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel.
Rocha SM; Nascimento D; Coelho RS; Cardoso AM; Passarinha LA; Socorro S; Maia CJ
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047621
[TBL] [Abstract][Full Text] [Related]
2. STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide.
Rocha SM; Nascimento D; Cardoso AM; Passarinha L; Socorro S; Maia CJ
Mol Med Rep; 2023 Feb; 27(2):. PubMed ID: 36660947
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens.
Gomes IM; Rocha SM; Gaspar C; Alvelos MI; Santos CR; Socorro S; Maia CJ
Med Oncol; 2018 Feb; 35(3):40. PubMed ID: 29464393
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
[TBL] [Abstract][Full Text] [Related]
5. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis of STEAP1 knockdown in human LNCaP prostate cancer cells.
Rocha SM; Santos FM; Socorro S; Passarinha LA; Maia CJ
Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119522. PubMed ID: 37315586
[TBL] [Abstract][Full Text] [Related]
7. TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
Sekino Y; Han X; Kawaguchi T; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Yasui W; Matsubara A
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412591
[TBL] [Abstract][Full Text] [Related]
8. Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis.
Brown SG; Knowell AE; Hunt A; Patel D; Bhosle S; Chaudhary J
Prostate; 2015 Feb; 75(3):266-79. PubMed ID: 25327819
[TBL] [Abstract][Full Text] [Related]
9. Exploiting epigenetic targets to overcome taxane resistance in prostate cancer.
Cevatemre B; Bulut I; Dedeoglu B; Isiklar A; Syed H; Bayram OY; Bagci-Onder T; Acilan C
Cell Death Dis; 2024 Feb; 15(2):132. PubMed ID: 38346967
[TBL] [Abstract][Full Text] [Related]
10. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Chao OS; Goodman OB
Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
[TBL] [Abstract][Full Text] [Related]
11. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
Sennoune SR; Nelius T; Jarvis C; Pruitt K; Kottapalli KR; Filleur S
PLoS One; 2020; 15(6):e0234078. PubMed ID: 32484838
[TBL] [Abstract][Full Text] [Related]
12. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
[TBL] [Abstract][Full Text] [Related]
13. Functional p53 determines docetaxel sensitivity in prostate cancer cells.
Liu C; Zhu Y; Lou W; Nadiminty N; Chen X; Zhou Q; Shi XB; deVere White RW; Gao AC
Prostate; 2013 Mar; 73(4):418-27. PubMed ID: 22996738
[TBL] [Abstract][Full Text] [Related]
14. [Infiltrating mast cells promote neuroendocrine differentiation and increase docetaxel resistance of prostate cancer cells by up-regulating p21].
Ou YH; Jiang YD; Li Q; Zhuang YJ; Dang Q; Tan WL
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jun; 38(6):723-730. PubMed ID: 29997096
[TBL] [Abstract][Full Text] [Related]
15. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
Paller CJ; Antonarakis ES
Drug Des Devel Ther; 2011 Mar; 5():117-24. PubMed ID: 21448449
[TBL] [Abstract][Full Text] [Related]
16. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
17. Preclinical profile of cabazitaxel.
Vrignaud P; Semiond D; Benning V; Beys E; Bouchard H; Gupta S
Drug Des Devel Ther; 2014; 8():1851-67. PubMed ID: 25378905
[TBL] [Abstract][Full Text] [Related]
18. Six transmembrane epithelial antigen of the prostate 1 is down-regulated by sex hormones in prostate cells.
Gomes IM; Santos CR; Socorro S; Maia CJ
Prostate; 2013 May; 73(6):605-13. PubMed ID: 23060075
[TBL] [Abstract][Full Text] [Related]
19. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
[TBL] [Abstract][Full Text] [Related]
20. ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro.
Oprea-Lager DE; Bijnsdorp IV; VAN Moorselaar RJ; VAN DEN Eertwegh AJ; Hoekstra OS; Geldof AA
Anticancer Res; 2013 Feb; 33(2):387-91. PubMed ID: 23393328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
